Javier Rojas Eugui’s Post

The healthcare industry is at a critical tipping point. At @GE HealthCare, we are focused on delivering on a future of healthcare that will be personalized and preventive, with better patient outcomes at lower costs. Great insights in the latest episode of @Nasdaq and Invesco QQQ’s Innovation Answered series from MedTech Finance Leaders, including our CFO @Jay Saccaro discussing the role @GEHC is playing in healthcare innovation. #GEHealthCare #FutureofHealthcare #AI #PrecisionCare https://lnkd.in/eHURMZmY

The healthcare industry is at a critical tipping point. At @GE HealthCare, we are focused on delivering on a future of healthcare that will be personalized and preventive, with better patient outcomes at lower costs. Watch the latest episode of @Nasdaq and Invesco QQQ’s Innovation Answered series to hear our CFO @Jay Saccaro discuss the role @GEHC is playing in healthcare innovation. #GEHealthCare #FutureofHealthcare #AI #PrecisionCare

The healthcare industry is at a critical tipping point. At GE HealthCare, we are focused on delivering on a future of healthcare that will be personalized and preventive, with better patient outcomes at lower costs. Watch the latest episode of Nasdaq and Invesco QQQ’s Innovation Answered series to hear our CFO Jay Saccaro 😊 discuss the role @GEHC is playing in healthcare innovation. #GEHealthCare #FutureofHealthcare #AI #PrecisionCare

🧬 European Life Sciences deals overview for 2023 & 2024 outlook 📈 https://lnkd.in/dsiQ5NpB Excited to share our latest publication. In this report, we delve into the dynamic landscape of life sciences investments across European targets, highlighting key trends across each deal type, notable deals, and emerging opportunities shaping the industry Explore the full report to stay informed and gain strategic perspectives on the future of life sciences investments in Europe #LifeSciences #Biotech #Investments

We had a very interesting panel discussion last week on the 2024 outlook for Biotech. We examined the drivers of the potential recovery in the Biotech capital markets and deal making and considered four levers: 1. The return of risk capital from institutional investors 2. 2030 Big Pharma patent cliff 3. More deals: Big Pharma M&A and licensing driven by profits from obesity / cardiometabolic and (2) need to find more first in class / best in class medicines to replace 2030 revenue 4. Dual track and Triple track options for Biotechs: sale to Big Pharma or IPO and / or licensing partnerships A poll of the ~150 participants felt cautiously optimistic that this was the beginning of a recovery in Biotech markets. It was a pleasure to moderate the discussion. Thanks to the excellent panel Marta Helena Lesko Tim Haines Jane Buus Laursen Michael Rice and to LSX - partnering for Life Science eXecutives Adam Griffiths for hosting.

#News for #Media and #Investors. Watch Brian Hoffmann, President Generics discuss the record performance of our Generics business in 2023. With double-digit revenue and core operating profit growth, this was an outstanding year for Generics. For more, see https://lnkd.in/e3wVpu2k https://lnkd.in/eFaQU_AG

#FundManagerNews 🗞 Merck Mercuriadis, founder of Hipgnosis Song Management, will step down as chair following Blackstone's acquisition of Hipgnosis Songs Fund, which has received unanimous shareholder approval. Read further 👉https://lnkd.in/gRWbCtGx If this affects you and you’d like to discuss our opinion on this fund and how it may or may not continue to fit your investment goals or risk tolerance, please call us on 01420 83517 or email info@murdochasset.co.uk #fundmanagement#investments#investing

I guess the team Pacific Equity Partners are big fans of Dr Nick from the Simpsons or maybe it’s just defensible assets? In any event it would appear that they are having a good look at Integral Diagnostics (IDX) as part of their second Secure Assets Fund. Integral Diagnostics (IDX) has struggled recently with a market cap of $490m on $89m of EBITDA. Radiology clinics have been somewhat of a darling for private equity presenting defensible assets with high barriers of entry and stable cashflows. It would appear that Pacific Equity Partners team led by Andrew Charlier, Paul Foster and Evan Hattersley are keen to get their teeth stuck into the sector with a possible takeover offer for underperforming Integral Diagnostics (IDX) being a logical entry point. Pacific Equity Partners are arguable the leading private equity firm for public to private transactions having completed a number of them with great success including the most recent of Healthia Limited Australia. I would expect that a deal will be done quickly if the target ticks the boxes for the team at PEP. Certainly plenty of action at the moment in listed and unlisted markets! #privateequity #takeover #mergersandacquisitions #corporateadvisory

As the #UNGA meets to discuss anti-microbial resistance, Tenmile has made an investment in Lumos Diagnostics, furthering our commitment to support commercial efforts to stem the threat of #AMR. How does Lumos play a role in this fight? About a month ago, there was a case of whooping cough (caused by Bordetella pertussis, a bacterial infection) in my daughter's pre-school. A week later my daughter started coughing and we promptly visited our GP. While the GP felt it was unlikely to be bacterial, the definitive test would take 2-3 days and so to be safe, recommended #antibiotics. As a parent, it's hard not to take this advice and promptly started antibiotic treatment. Three days later we got the news that it was not a bacterial infection. There was no need for antibiotics, yet we've already exposed our daughters microbiome out of caution, becoming a part of a scary statistic. Approximately 30% of antibiotics are prescribed when they aren't necessary. This is where FebriDx steps in. Lumos has developed FebriDx as a point-of-care diagnostic to distinguish bacterial from non-bacterial infections. In 10 minutes, a GP could have identified that my daughter's cough was not caused by a bacterial infection and that antibiotics would not help. Along with novel antibiotics (Revagenix, Inc.) and vaccines (LimmaTech Biologics AG), #diagnostics will play a key role in identifying bacterial infections, avoiding over-prescription and reducing the burden of AMR.

Watch: A conversation on the current landscape for capital markets and expected trends for 2024, with a particular focus on the healthcare and life sciences industry, including: -A summary of recent market activity. -Characteristics of life sciences companies that have successfully exited or raised capital. -Specific industries of investor focus. -Considerations for healthcare and life sciences companies preparing to go public. This Cooley Market Talks session will feature Goldman Sachs' Sonia Gupta + Cooley capital markets co-chairs, Charlie Kim and David Peinsipp. Register here for the virtual event or to receive the on-demand recording: https://bit.ly/3SGtPpF #CooleyMarketTalks #capitalmarkets #healthcare #lifesciences